<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163263">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02082496</url>
  </required_header>
  <id_info>
    <org_study_id>MC4R-2014</org_study_id>
    <nct_id>NCT02082496</nct_id>
  </id_info>
  <brief_title>GLP-1 Response and Effect in Individuals With Obesity Causing Genetic Mutations</brief_title>
  <official_title>Exploration of the Physiological Effect of GLP-1 in Obese Adults Diagnosed With an Obesity Causing Genetic Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <authority>Denmark: Ethics Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The obesity epidemic is attributable to dietary and behavioral trends acting on a person's
      genetic makeup to determine body mass and susceptibility to obesity-related disease. Common
      forms of obesity have a strong hereditary component and many genetic pathways that
      contribute to obesity have already ben identified.

      Glucagon-like peptide (GLP) -1 is an incretin hormone that potentiates glucose-stimulated
      insulin secretion. However, GLP-1 also acts as an appetite-inhibiting hormone affecting the
      appetite center in the hypothalamus. Today, GLP-1 agonists are available for treatment of
      type 2 diabetes, and their treatment potential in obesity is an area of active research.

      The aim of this study is to explore if the appetite inhibiting effect of GLP-1 is intact in
      people diagnosed wth an obesity causing genetic disorder and to investigate the
      physiological role of GLP-1 on food intake and appetite regulation in this group. The
      investigators hypothesis is that GLP-1 can form the basis of obesity treatment in patients
      with obesity causing genetic disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Exploration of the physiological role of GLP-1 concerning food intake and appetite
           regulation in obese adults diagnosed with an obesity related genetic disorder.

        -  Assessment of the effect of GLP-1 on body composition, bone mineral density, energy
           expenditure, cardiac function, glucose tolerance, insulin sensitivity, lipid
           concentrations and neuroendocrine function.

        -  Assessment of the impact of the leptin induced adaptive thermogenesis response in the
           weight reduced study participants.

        -  Investigating the alteration of the composition of gut bacteria as well as subjective
           ratings of satiety and hunger before after supplement with GLP-1.
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <phase>N/A</phase>
  <study_type>Expanded Access</study_type>
  <study_design>N/A</study_design>
  <condition>Obesity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>S.c. liraglutide 3.0mg once daily</description>
    <other_name>Victoza, Novo Nordisk A/S in DK-2880 Bagsvaerd</other_name>
    <other_name>Serial number:76477425</other_name>
    <other_name>International code name: 005</other_name>
    <other_name>US Class Codes: 006, 018, 044, 046, 051, 052</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI  above 28 (kg/m2)

          -  age 18-65 years

          -  otherwise healthy

        Exclusion Criteria:

          -  pregnancy or breastfeeding

          -  Type 2 Diabetes

          -  suffering from severe medical conditions
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jens J Holst, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eva Pers Winning Iepsen, M.D.</last_name>
    <phone>+45-40841896</phone>
    <email>eva.winning@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Signe S. Torekov, Assistant Professor</last_name>
    <phone>+45 353 27509</phone>
    <email>torekov@sund.ku.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Biomedical Sciences</name>
      <address>
        <city>Copenhagen</city>
        <zip>2200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Eva Pers Winning Iepsen, M.D.</last_name>
      <phone>+45-40841896</phone>
      <email>eva.winning@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Signe S. Soerensen, Assistant Professor</last_name>
      <phone>+45 353 27509</phone>
      <email>torekov@sund.ku.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 14, 2014</lastchanged_date>
  <firstreceived_date>March 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Eva Pers Winning Iepsen</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Obesity Genetics</keyword>
  <keyword>GLP-1</keyword>
  <keyword>GLP-1 Receptor Agonists</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
